PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
140.15
Positive P/E while Drug Manufacturers - Specialty & Generic median is negative at -1.66. Peter Lynch would investigate competitive advantages in a distressed Drug Manufacturers - Specialty & Generic.
73.08
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.43. Jim Chanos would check for potential multiple compression risks.
5.34
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.81. Jim Chanos would check for potential asset write-down risks.
-131.29
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -7.90. Seth Klarman would investigate cash flow improvement potential.
-298.73
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -5.40. Seth Klarman would investigate operational improvement potential.
5.34
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.82. Jim Chanos would check for valuation bubble risks.
0.18%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-0.76%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.08%. Seth Klarman would investigate cash flow improvement potential.